To hear about similar clinical trials, please enter your email below
Trial Title:
Real World Study of Linperlisib for Lymphoma Treatment
NCT ID:
NCT05863871
Condition:
Focus on the Lymphoma Including B/T-cell Lymphoma
Conditions: Official terms:
Lymphoma
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Drug
Intervention name:
Linperlisib
Description:
80 mg, qd
Arm group label:
all enrolled patients
Other name:
YY-20394
Summary:
This is a multicenter, non-interventional and observational real-world study to evaluate
the efficacy and safety of linperlisib in patients with lymphoma.
Criteria for eligibility:
Study pop:
Clinical diagnosis of lymphoma
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Age ≥18 years
2. Clinical diagnosis of lymphoma patients
3. Patients signed informed consent, volunteered to join the study, and had the
willingness and ability to cooperate with the data collection in this study;
4. The researchers' assessment can use Linperlisib treatment
Exclusion Criteria:
1. The nature of the study could not be understood or informed consent was not obtained
2. Other ineligible conditions were assessed by the investigator
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Address:
City:
Shanghai
Country:
China
Contact:
Last name:
Weili Zhao
Email:
zwl_trial@163.com
Facility:
Name:
Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital
Address:
City:
Tianjin
Country:
China
Contact:
Last name:
Huilai Zhang
Email:
zhlwgq@126.com
Start date:
May 2023
Completion date:
June 2027
Lead sponsor:
Agency:
Ruijin Hospital
Agency class:
Other
Collaborator:
Agency:
Tianjin Medical University Cancer Institute and Hospital
Agency class:
Other
Source:
Ruijin Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05863871
